0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > CD20 > CD0-H52H3

Human CD20 / MS4A1 Full Length Protein, His Tag (HEK293) (SPR verified)

  • Synonym
    MS4A1,CD20,MS4A-1
  • Source
    Human CD20 Full Length, His Tag (HEK293) (SPR verified) (CD0-H52H3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
    Predicted N-terminus: Met 1
  • Molecular Characterization
    Online(Met 1 - Pro 297) P11836-1

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 35.2 kDa. The protein migrates as 40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >85% as determined by SDS-PAGE.

  • Formulation

    Delivered as bulk protein in a 0.2 μm filtered solution of 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.

    This product is not suitable for cell based experiments due to cytotoxicity of DDM.
    DDM and CHS are INDISPENSABLE to keep CD20 soluble and active, under no circumastance should you remove DDM and CHS.
    DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
    If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.
    Contact us for customized product form or formulation.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • Shipping
    This product is supplied as sterile liquid solution and shipped frozen with dry ice, please inquire the shipping cost.
SDS-PAGE
Human CD20 Full Length, His Tag (HEK293) (SPR verified) (Cat. No. CD0-H52H3) SDS-PAGE gel

Human CD20 Full Length, His Tag (HEK293) (SPR verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 85%.

Bioactivity-ELISA
Human CD20 Full Length, His Tag (HEK293) (SPR verified)Human CD20 Full Length, His Tag (HEK293) (SPR verified) (Cat. No. CD0-H52H3) ELISA bioactivity

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with a linear range of 0.4-3 ng/mL (in presence of DDM and CHS) (QC tested).

Human CD20 Full Length, His Tag (HEK293) (SPR verified)Human CD20 Full Length, His Tag (HEK293) (SPR verified) (Cat. No. CD0-H52H3) ELISA bioactivity

Immobilized Ofatumumab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with a linear range of 0.4-6 ng/mL (in presence of DDM and CHS) (QC tested).

Human CD20 Full Length, His Tag (HEK293) (SPR verified)Human CD20 Full Length, His Tag (HEK293) (SPR verified) (Cat. No. CD0-H52H3) ELISA bioactivity

Immobilized Human CD20 Full Length, His Tag (HEK293) (SPR verified) (Cat. No. CD0-H52H3) at 5 μg/mL (100 μL/well) can bind Biosimilar of Obinutuzumab with a linear range of 0.3-5 ng/mL (Routinely tested).

Bioactivity-SPR
Human_FcRn_Heterodimer_Protein_SPR

MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with an affinity constant of 6.21 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (QC tested).

Human_FcRn_Heterodimer_Protein_SPR

Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) captured on CM5 chip via Anti-His antibody can bind MabThera® (Rituximab) with an affinity constant of 0.921 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Bioactivity-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Rituximab on AHC Biosensor, can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with an affinity constant of 1.14 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Human_FcRn_Heterodimer_Protein_Bli

Loaded Ofatumumab (Human IgG1) on AHC Biosensor, can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with an affinity constant of 0.968 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
  • References
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $780.00

Price(USD) : $2900.00

Price(USD) : $6600.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:20 Details
  • Number of Drugs in Clinical Trials:80 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop